VanEck Pharmaceutical ETF
PPH
44 hedge funds and large institutions have $122M invested in VanEck Pharmaceutical ETF in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 8 closing their positions.
2.94% less ownership
Funds ownership: 47.22% → 44.28% (-2.9%)
6% less capital invested
Capital invested by funds: $131M → $122M (-$8.35M)
10% less funds holding
Funds holding: 49 → 44 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$349K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$127K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$59.4K |
| 4 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$46.7K |
| 5 |
LPL Financial
San Diego,
California
|
+$39.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$8.67M |
| 2 |
VF
Virtu Financial
New York
|
-$2.02M |
| 3 |
Morgan Stanley
New York
|
-$1.99M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.61M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.45M |
PPH Hedge Fund Activity: Q3 2018 in Review
44 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2018, worth a combined $122M — down 6.4% from $131M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of PPH and 3 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 6 added.
The largest buyer was Janney Montgomery Scott, opening a new position worth an estimated $349K. The largest seller was Brinker Capital Investments, exiting entirely with an estimated $8.67M sold.
- 44 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2018, down from 49 in Q2 2018.
- Funds reported $122M of VanEck Pharmaceutical ETF stock for Q3 2018, down 6.4% quarter-over-quarter.
- 3 funds opened new VanEck Pharmaceutical ETF positions in Q3 2018 and 8 closed out, a net change of -5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2018 was Janney Montgomery Scott, an estimated $349K added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2018 was Brinker Capital Investments, an estimated $8.67M sold.
Based on aggregated 13F filings for Q3 2018.